Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ocugen, Inc. Director's Dealing 2021

May 6, 2021

32915_dirs_2021-05-05_7c5ffa89-c200-4574-a306-a7af2abe7c4c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ocugen, Inc. (OCGN)
CIK: 0001372299
Period of Report: 2021-05-04

Reporting Person: Tammara Vijay (Senior Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-04 Common Stock M 4900 $0.46 Acquired 4900 Direct
2021-05-04 Common Stock S 4900 $13.81 Disposed 0 Direct
2021-05-04 Common Stock M 2000 $2.94 Acquired 2000 Direct
2021-05-04 Common Stock S 2000 $13.81 Disposed 0 Direct
2021-05-04 Common Stock M 6500 $0.51 Acquired 6500 Direct
2021-05-04 Common Stock S 6500 $13.5 Disposed 0 Direct
2021-05-04 Common Stock M 2311 $0.565 Acquired 2311 Direct
2021-05-04 Common Stock S 2311 $13.81 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-05-04 Options (Right to Buy) $0.46 M 4900 Disposed 2024-09-18 Common Stock (4900) Direct
2021-05-04 Options (Right to Buy) $2.94 M 2000 Disposed 2026-04-26 Common Stock (2000) Direct
2021-05-04 Options (Right to Buy) $0.51 M 6500 Disposed 2030-01-02 Common Stock (6500) Direct
2021-05-04 Options (Right to Buy) $0.565 M 2311 Disposed 2030-08-14 Common Stock (2311) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.35 to $13.71. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: All of the options became exerciable immediately upon grant.

F4: The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates.

F5: The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on September 14, 2020, subject to continued service with the Company on the applicable vesting dates.